In T2DM-CKD patients, consider the use of SGLT-2i (eGFR ≥ 20 ml/min/1.73 m2), GLP-1RA, or non-steroidal mineralocorticoid receptor antagonists (eGFR ≥ 25 ml/min/1.73 m2) (A); 3. Here, NR3C2 is linked to chronic kidney disease.